Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (385)	12/29/1999 12:03:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1834

[ off topic, apologies ] >> So, where are we today? << I'm still focused on the patent claims, but, for new stuff, there's also this in addition to the Solvay project..... The Company's scientists have identified a potent and selective antagonist for the A1 receptor. This proprietary non-nucleoside compound has advanced through initial efficacy testing in animal models. Adenosine A2b-selective antagonists as well as antagonists with dual selectively for adenosine A1 and A2b receptors have been identified. The Company's scientists have also identified subtype-specific antagonists of A2a and A3 as well as non-nucleoside based agonists for the adenosine A2a receptor subtypes that may have application to therapeutic indications other than asthma.